Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The oral GLP-1 market is witnessing strong growth, driven by rising prevalence of type 2 diabetes and obesity, increasing patient preference for oral therapies, and continuous pharmaceutical innovations
While semaglutide will remain a foundational therapy in the class, the markets center of gravity is shifting toward multi-agonist and combination-based innovations that deliver higher efficacy with comparable safety and durability
Novo Nordisk Inc
Enjoy hundreds of yoga, pilates, boxing, dance, and nutrition classes included in your GLP-1 plan
Cheng serves as a consultant/advisory board member for Abbott Diabetes Care, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly and Company, HLS Therapeutics, Insulet, Janssen, Novo Nordisk, and Sanofi
